Improved method for therapeutic drug monitoring of 6-thioguanine nucleotides and 6-methylmercaptopurine in whole-blood by lc/msms using isotope-labeled internal standards

Therapeutic Drug Monitoring

Volumn 35, Issue 3, 2013, Pages 313-321

  Kirchherr, Hartmut ^a   Shipkova, Maria ^b   Ahsen, Nicolas Von ^a  

^a Medizinisches Labor Bremen   (Germany)

^b Zentralinstitut für Klinische Chemie und Laboratoriumsmedizin   (Germany)

Author keywords

6 mercaptopurine; Azathioprine; Mass spectrometry; Thiopurine drug monitoring; Whole blood

Indexed keywords

6 METHYLTHIOINOSINE; EDETIC ACID; HEMOGLOBIN; TIOGUANINE;

ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MONITORING; ELECTROSPRAY; ERYTHROCYTE; HEMOGLOBIN DETERMINATION; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

6-MERCAPTOPURINE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; ERYTHROCYTES; GUANINE NUCLEOTIDES; HUMANS; LIMIT OF DETECTION; TANDEM MASS SPECTROMETRY; THIONUCLEOTIDES; TIME FACTORS;

EID: 84880081350     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318283ed5d     Document Type: Article

References (37)

1. Elion GB. The purine path to chemotherapy. Science. 1989;244:41-47. (Pubitemid 19130741)
2. de Boer NK, van Bodegraven AA, Jharap B, et al. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:686-694. (Pubitemid 350199222)
3. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29:601-605. (Pubitemid 32275544)
4. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025-1030. (Pubitemid 30346978)
5. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr. 1987;423:169-178. (Pubitemid 18026294)
6. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992;583:83-90.
7. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem. 1998;44:551-555. (Pubitemid 28141350)
8. Shipkova M, Armstrong VW, Wieland E, et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem. 2003;49:260-268. (Pubitemid 36143448)
9. Pike MG, Franklin CL, Mays DC, et al. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B Biomed Sci Appl. 2001;757:1-9. (Pubitemid 32424452)
10. Erb N, Haverland U, Harms DO, et al. High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796:87-94. (Pubitemid 38352712)
11. Heuck CC, Reinauer H, Wood WG. The alkaline haematin detergent (AHD575) method for the determination of haemoglobin in blood-A candidate reference measurement procedure. Clin Lab. 2008;54:255-272.
12. Mawatari H, Kato Y, Nishimura S, et al. Reversed-phase high-performance liquid chromatographic assay method for quantitating 6-mercaptopurine and its methylated and non-methylated metabolites in a single sample. J Chromatogr B Biomed Sci Appl. 1998;716:392-396. (Pubitemid 28464589)
13. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557. (Pubitemid 32217566)
14. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030. (Pubitemid 36830428)
15. Jansen RS, Rosing H, Schellens JH, et al. Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrom Rev. 2011;30:321-343.
16. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:293-300. (Pubitemid 43075465)
17. Dervieux T, Meyer G, Barham R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005;51:2074-2084. (Pubitemid 41532623)
18. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit. 2005;27:647-654. (Pubitemid 41437645)
19. Vikingsson S, Carlsson B, Almer SH, et al. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther Drug Monit. 2009;31:345-350.
20. Keuzenkamp-Jansen CW, De Abreu RA, Bokkerink JP, et al. Determination of extracellular and intracellular thiopurines and methylthiopurines by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995;672:53-61.
21. Neurath MF, Kiesslich R, Teichgraber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3:1007-1014. (Pubitemid 41415749)
22. Hofmann U, Heinkele G, Angelberger S, et al. Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry. Anal Chem. 2012;84:1294-1301.
23. Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2003;5:506-511. (Pubitemid 38915051)
24. Derijks LJ, Gilissen LP, Hooymans PM, et al. Thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715-729.
25. Reinshagen M, Schütz E, Armstrong VW, et al. 6-Thioguanine nucleotide-Adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem. 2007;53:1306-1314. (Pubitemid 47020987)
26. de Graaf P, Vos RM, de Boer NH, et al. Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878: 1437-1442.
27. Chouchana L, Narjoz C, Beaune P, et al. The benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:15-36.
28. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut. 2004;53:1123-1128. (Pubitemid 38961966)
29. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther. 2007;26:217-225. (Pubitemid 46985496)
30. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3(suppl 1):S30-S38. (Pubitemid 36395165)
31. Armstrong VW, Shipkova M, von Ahsen N, et al. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit. 2004; 26:215-219.
32. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149-1157. (Pubitemid 41602556)
33. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89:387-391.
34. van Egmond R, Chin P, Zhang M, et al. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther. 2012;35:1181-1189.
35. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209-214. (Pubitemid 46216945)
36. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640-647.
37. Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol. 2011;17:4166-4173.